Catheter Precision Reveals Promising Data at SCRN Meeting

Catheter Precision, Inc. (NYSE American:VTAK), a notable U.S. medical device company, has unveiled significant clinical data from the VIVO EU Registry during the Society of Cardiac Robotic Navigation meeting in Lisbon. The data highlights key findings from 27 subjects at Hospital da Luz, where 18 underwent ablation procedures.

The results showed a 100% accuracy in pinpointing the arrhythmia's origin. Approximately 95% of the procedures were deemed successful, and 83% of patients experienced no recurrence of arrhythmia 12 months after the procedure. These outcomes underscore the potential of Catheter Precision's VIVO system to enhance decision-making and long-term patient results.

CEO David Jenkins emphasized VIVO's accuracy and anticipates further comprehensive study results involving seven additional trials. The company's focus remains on elevating cardiac arrhythmia treatments through innovative electrophysiology technologies.